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Accumulation of the amyloid-beta (Aβ) peptide is a central factor in Alzheimer’s disease
(AD) pathogenesis as supported by continuing evidence. This review concisely summarizes
this evidence supporting a critical role for Aβ in AD before discussing the clearance
of this peptide. Mechanisms of clearance of Aβ are critical for preventing pathological
elevations in Aβ concentration. Direct degradation of Aβ by endopeptidases has emerged
as one important pathway for clearance. Of particular interest are endopeptidases that are
sensitive to the neprilysin (NEP) inhibitors thiorphan and phosphoramidon (i.e., are “NEP-
like”) as these inhibitors induce a dramatic increase in Aβ levels in rodents. This review
will focus on neprilysin-2 (NEP2), a NEP-like endopeptidase which cooperates with NEP to
control Aβ levels in the brain. The evidence for the involvement of NEP2 in AD is discussed
as well as the therapeutic relevance with regards to gene therapy and the development of
molecular markers for the disease.
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THE AMYLOID CASCADE HYPOTHESIS
AMYLOID-BETA PRODUCTION
Alzheimer’s disease (AD) is a devastating neurodegenerative dis-
order that leads to behavioral, cognitive, and memory deficits.
Familial AD (FAD) is inherited in an autosomal dominant pattern
with symptoms typically presenting in the 4th or 5th decade
of life. Sporadic late onset AD (LOAD) has a much later age
of onset, usually beginning in the 7th–8th decade. Confirmed
post mortem, AD pathology shows accumulations of extracel-
lular amyloid-beta (Aβ) containing plaques and intracellular
neurofibrillary tau tangles in the brain. The involvement of Aβ
in AD is a prerequisite to the significance of Aβ clearance to
AD. Therefore, we will present a rationale for the clear link
between Aβ and AD progression. The formation of Aβ has
been well studied (Goedert and Spillantini, 2006; Roberson and
Mucke, 2006). In the amyloidogenic pathway, APP is first cleaved
by β-secretase (BACE1) at amino acid 1 (of Aβ). When the
resulting C-terminal fragment, C99, undergoes γ-secretase cleav-
age, it releases the amyloidogenic Aβ peptide. Key proteolytic
components of γ-secretase are presenilin-1 and 2 (PS1, PS2).
While various Aβ peptide lengths are produced by γ-secretase,
it is Aβ42 and Aβ40 that have received the most attention. The
additional two hydrophobic residues in Aβ42 increase its ability
to aggregate, providing the scaffold for oligomeric and fibril-
lar forms of Aβ (Jarrett and Lansbury, 1993; Iwatsubo, 1998).
It should be noted that Aβ is a naturally occurring endoge-
nous peptide that may have normal physiological functions. For
example, it has been shown that picomolar concentrations of
Aβ increased LTP resulting in improved synaptic plasticity and
memory (Puzzo et al., 2008, 2012; Morley et al., 2010). Therefore,
pathology associated with Aβ is related to its aberrant accumula-
tion/aggregation.
AMYLOID-BETA AND ALZHEIMER’S DISEASE
Familial forms of early-onset AD are caused by mutations in
APP, PS1, or PS2 or through increased copy number of APP
(Wisniewski et al., 1985; Prasher et al., 1998; Rovelet-Lecrux et al.,
2006). All of the roughly 180 mutations in PS1, 20 mutations
in PS2, and 36 mutations in APP lead to elevations of total Aβ,
the Aβ42:Aβ40 ratio, or its aggregation (Pimplikar, 2009). Within
the Aβ sequence, point mutations, including the Arctic mutation,
have been linked to increased aggregation of Aβ into protofibrils
and fibrils (Clements et al., 1993, 1996; Nilsberth et al., 2001;
Cheng et al., 2004; Walsh et al., 2007), as well as to reduced
clearance of this peptide (Tsubuki et al., 2003; Kaden et al., 2012).
However, the Arctic mutation does not affect cleavage and pro-
cessing of APP; thus, this is an Aβ-only defect. Therefore, the only
commonality between all the familial mutations is the effect on
properties related to Aβ. To our knowledge, no other major neu-
rodegenerative disease has familial forms that all genetically point
to one common factor with the exception of monogenetic diseases
like Huntington’s disease. This hypothesis is bolstered by the dis-
covery of a protective mutation in APP in an Icelandic population
that reduces BACE1 proteolysis and lowers Aβ levels (Jonsson
et al., 2012). As would be consistent with the amyloid hypothesis,
this mutation is associated with protection from developing AD
as well as from normal cognitive decline with aging.
Unfortunately, therapies aimed at Aβ have been less than
impressive in clinical trials. Most recently, Aβ-targeting mon-
oclonal antibodies, such as bapineuzumab and solanezumab,
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have failed to reach their desired cognitive endpoints in trials
of mild/moderate AD (Salloway et al., 2009, 2014; Farlow et al.,
2012; Doody et al., 2014). Bapineuzumab did show trends for
reduced Aβ42 levels and Aβ42:Aβ40 ratio, however, some subjects
continued to demonstrate cognitive decline (Roher et al., 2013).
Additionally, γ-secretase inhibitors (GSI) also failed to produce
beneficial results, and were actually found to worsen cognitive
function. It is believed that off-target effects, such as effects on
the cleavage of notch by PS1 may have participated in producing
this poor response and data suggest that the proper timing of GSIs
is integral to their successful treatment of AD (Abramowski et al.,
2008). In general it is unclear to what degree and for what period
of time one would need to reduce Aβ levels to slow down, halt, or
possibly reverse the pathology of AD. Likely, early intervention,
before extensive pathological alterations occur, will be needed to
effectively treat AD using anti-Aβ approaches.
EVIDENCE FOR THE IMPORTANCE OF AMYLOID-BETA IN SPORADIC
ALZHEIMER’S DISEASE
Regardless of the excuses for the failures of the many anti-Aβ
clinical trials, these disappointments have understandably cast
doubt over the amyloid hypothesis of AD. While the familial
genetics clearly points to Aβ as a critical factor in the etiology
of AD, it is conceivable that the much more common sporadic
form of the disease (i.e., LOAD) has a distinct root cause(s)
that is not dependent on Aβ. While this is a possibility, several
lines of evidence suggest otherwise. First, these two forms of AD
have very similar pathology (Lippa et al., 1996), supporting a
common cause/progression. Second, if LOAD was not linked to
Aβ, then polymorphisms associated with risk would be predicted
to not affect Aβ. Indeed, there are many mutations affecting risk
for LOAD and many of these polymorphisms are not obviously
linked to Aβ; however, many others can be clearly linked to Aβ
(Tanzi, 2012; Griciuc et al., 2013). What is even more important
is that some of the most significant effectors of risk occur in
genes strongly linked to Aβ. The most noteworthy of these are
polymorphisms in the apolipoprotein E (apoE) gene with the
ε4 mutation (cys112arg) multiplying risk by about 3-fold per
inherited allele (Bu, 2009). ApoE can affect Aβ in multiple ways
including its aggregation, clearance, and catabolism (Bales et al.,
1999; Holtzman et al., 2000; Shibata et al., 2000; Fagan et al., 2002;
Dolev and Michaelson, 2004; Koistinaho et al., 2004; Manelli
et al., 2004; Dodart et al., 2005; Bu, 2009; Belinson et al., 2010;
Hashimoto et al., 2012; Kline, 2012). Related to this, Jiang et al.
(2008) showed that apoE promotes proteolytic degradation of
Aβ by microglia. Another risk factor gene mutation has been
discovered in ABCA7 which affects risk at a comparable level to
the ε4 form of apoE (∼3-fold) and has also been linked to the
clearance of Aβ (Kim et al., 2013; Reitz et al., 2013). Third, if Aβ
were not involved in sporadic AD then a mutation reducing Aβ
production would not protect from LOAD. However, the Icelandic
APP mutation (discussed above) reduces risk of the sporadic form
of AD, again implicating Aβ in LOAD (Jonsson et al., 2012). These
lines of evidence strongly support a critical role for Aβ in the
pathogenesis of the more frequent sporadic form of the disease.
Perhaps the most common argument against the amyloid
hypothesis is the fact that plaque burden correlates poorly with
cognitive decline (Sorrentino et al., 2014). This discrepancy could
be partially explained by current theories indicating soluble
oligomeric forms of Aβ are the primary mediator of disease and
not the insoluble fibrillar amyloid. However, there may be a
more fundamental explanation. If Aβ is an initiator of the long
and complex cascade of pathologic alterations that take place in
AD, then a multitude of downstream effectors and modifying
factors (including genetics, other medical conditions, and envi-
ronment) would have a profound effect on the rate and severity
of disease progression (Korf et al., 2004; Bennett et al., 2006;
Barberger-Gateau et al., 2007; Ngandu et al., 2007; van Vliet et al.,
2009; Chang et al., 2010; Rusanen et al., 2011; Reijmer et al.,
2012; Tolppanen et al., 2013; Virta et al., 2013). In this scenario
one would predict that Aβ would correlate more poorly (but
still significantly) with cognitive decline while more downstream
effectors (e.g., synaptic loss) would correlate better (Bennett et al.,
2003, 2005).
AMYLOID-BETA CLEARANCE
In humans, Aβ is estimated to have a physiological production
rate of 7.6% per hour and a clearance rate of 8.3% per hour
(Bateman et al., 2006). The various mechanisms of removal
provide greater Aβ clearance than production, thus limiting its
accumulation. Interestingly, human data provide evidence that
accumulation in LOAD results from impaired clearance rather
than increased production of Aβ (Mawuenyega et al., 2010). Using
a technique of in vivo labeling, Mawuenyega et al. found that the
clearance rate of Aβ42 in AD individuals was reduced to 5.3%
per hour from 7.6% per hour in controls. Likewise, the Aβ40
clearance rate was reduced to 5.2% per hour from 7.0% per
hour in controls. This finding emphasizes the importance of Aβ
clearance in AD.
The proteolytic degradation of Aβ is a major route of clear-
ance. A variety of Aβ degrading enzymes have been found and this
topic has been comprehensively reviewed (Miners et al., 2011a;
Nalivaeva et al., 2012). Of these enzymes, neprilysin (NEP) is
considered one of the most important for the control of cerebral
Aβ levels. NEP is a member of the metalloprotease 13 (M13)
family of zinc metalloproteases. This 97 kD cell surface-associated
enzyme functions in the periphery and central nervous system
where it has been shown to degrade small peptides (Turner et al.,
2001). The 50 amino acid catalytic core cleaves on the N-terminal
side of hydrophobic residues (Kerr and Kenny, 1974a,b; Howell
et al., 1995). Using radiolableled Aβ, Iwata et al. (2000) showed
that Aβ42 primarily underwent degradation by NEP in their in
vivo assay. Furthermore, application of inhibitors to NEP in rat
brain produced dramatic elevations of endogenous Aβ resulting
in plaque deposition. This effect was independently replicated
in mice (Dolev and Michaelson, 2004; Nisemblat et al., 2008).
Further supporting NEP as a critical Aβ-degrading enzyme is the
observation that NEP overexpression imparts significant reduc-
tions in Aβ plaque deposition in APP-transgenic mice (Marr
et al., 2003), and in some experiments, improved cognitive per-
formance (reviewed in Marr and Spencer, 2010). It has also
been shown that NEP mRNA and protein expression levels are
reduced in association with age or in AD subjects (Reilly, 2001;
Yasojima et al., 2001a,b; Iwata et al., 2002; Apelt et al., 2003;
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Caccamo et al., 2005; Maruyama et al., 2005; Wang et al.,
2005, 2010); however, this notion has been seriously challenged
more recently. Miners and colleagues have used a highly specific
enzyme-immunocapture/activity assay to show that NEP activity
levels increase with age and during the progression of AD (Miners
et al., 2009, 2010, 2011b). This is similar to the consensus on most
endopeptidase expression levels in association with AD (Miners
et al., 2011a), and may reflect a homeostatic response to the abun-
dance of Aβ substrate and/or to the inflammatory environment
occurring in AD. Regardless, these increased endogenous levels of
Aβ-degrading enzymes are ultimately insufficient to prevent the
accumulation and aggregation of Aβ in AD.
Despite the data demonstrating the importance of NEP in
enzymatic degradation of Aβ, other enzymes are clearly worthy
of clinical study. For example, NEP knockout mice show only a
moderate (1.5–2 fold) increase in Aβ levels that are far from the
levels needed to induce plaque deposition, as observed with NEP
inhibitors, until very advanced age (Iwata et al., 2001; Madani
et al., 2006). This modest increase in Aβ raises the possibility of
alternative Aβ degrading-enzymes that are likewise sensitive to
NEP-inhibitors (i.e., are NEP-like).
NEPRILYSIN-2
In the search for alternate Aβ degrading enzymes, NEP-like
proteases are important because of their potential involvement
in the spike in Aβ levels post treatment with NEP inhibitors.
One such enzyme is neprilysin-2 (NEP2). NEP2 is also a zinc
metalloendopeptidase belonging to the same M13 family as NEP.
It has also been demonstrated in rodents that NEP2 is sensitive
to the same NEP inhibitors, phosphoramidon and thiorphan
(Ikeda et al., 1999; Ghaddar et al., 2000; Shirotani et al., 2001).
NEP2 was first discovered while searching for an enzyme to
degrade endothelin in endothelin converting enzyme-1 knock-
out mice and found to be a secreted peptide, termed soluble-
secreted endopeptidase (SEP; Ikeda et al., 1999). Since then,
it has also been referred to as neprilysin-like protein (NEPLP
and Nl1) in mice and membrane-bound metalloendopeptidase-
like enzyme 1 or 2 (MMEL1/2) in humans (Ghaddar et al.,
2000; Bonvouloir et al., 2001; Shirotani et al., 2001). It is the
closest homolog to NEP, with 55% sequence identity and simi-
lar catalytic sites. Structural modeling of NEP2 using sequence
alignment and the crystal structure of NEP projects 97% iden-
tity in the active sites of these two enzymes (Voisin et al.,
2004). Due to alternative splicing, murine NEP2 can exist in a
membrane-bound form (mNEP2-α) or a secreted form (mNEP2-
β; Figure 1). Alternative splicing also acts on the human form of
NEP2 creating several isoforms. Human NEP2-β was found to
be localized to both the extracellular surface and to be secreted,
likely due to inefficient furan-like processing as a result of a
proline residue near the processing site (P’2; Bonvouloir et al.,
2001).
NEP2 SUBSTRATES AND LOCALIZATION
In a study by Shirotani et al. (2001) using membrane-bound
fractions, mNEP2-α was shown to have slower and weaker Aβ40
degrading properties when compared to NEP (with little to no
effect on Aβ42), and mNEP2-β/γ had nearly undetectable activity
against Aβ. However, subsequent studies using live cell assays
demonstrated that mNEP2-α and hNEP2-β are able to degrade
Aβ40, and more importantly, Aβ42 with comparable efficiency
with NEP (Huang et al., 2008; Hafez et al., 2011; Figure 1).
Interestingly, this activity was also not secreted into the cell culture
medium for hNEP2-β even though the protein can be found there.
hNEP2-γ did not show secreted Aβ-degrading activity or activity
at the cell surface. Despite the numerous similarities between
NEP2 and NEP, differences do exist. While the substrate speci-
ficities are very similar (particularly in rodents) their localizations
suggest divergent roles in the central nervous system. Studies in
rodents have shown that, while NEP2 is expressed at variable
levels in most brain regions, it is most highly expressed in the
brain stem, hypothalamus and pituitary (Ouimet et al., 2000;
Facchinetti et al., 2003). Considering this localization and the
substrates cleaved (e.g., gonadotropin-releasing hormone) a role
in the metabolism of neuropeptides of the hypothalamo-pituitary
axis has been suggested (Rose et al., 2002). Unlike NEP, NEP2
is highly expressed in the testis and brain (Bonvouloir et al.,
2001), and NEP2 knockout mice do show reduced sperm function
(Carpentier et al., 2004). Furthermore, hNEP2 was found to have
a more restricted substrate specificity compared to hNEP with
less activity against several vasoactive peptides (Whyteside and
Turner, 2008). More comprehensive reviews of NEP2 are available
(Marr and Spencer, 2010; Marr, 2013).
NEP2 IN ALZHEIMER’S DISEASE
NEP2 knockout experiments have demonstrated the importance
of NEP2 in amyloid regulation (Hafez et al., 2011). Using mice
deficient for the NEP2 gene (Carpentier et al., 2004), Hafez et al.
(2011) reported significant elevations in total Aβ species in the
hippocampus and brainstem/diencephalon (∼1.5-fold). Increases
in Aβ accumulation were more dramatic in NEP2 knockout
mice crossbred with APP transgenic mice. In NEP/NEP2 double-
knockout mice, Aβ levels were again increased (∼1.5- to 2-fold),
compared with NEP−/−/NEP2+/+ controls. Treatment of these
double-knockout mice with phosphoramidon-infusing pumps
resulted in significant elevations in Aβ. This significant eleva-
tion in Aβ levels was also observed with intranasal treatment
of phosphoramidon in both wild-type and NEP/NEP2 double-
knockout mice suggesting that yet other NEP-like Aβ-degrading
endopeptidases are contributing to Aβ-catabolism (Hanson et al.,
2010; Hafez et al., 2011).
The importance of NEP2 was further explored in human
studies. Using brain tissue from various brain regions of non-
impaired, mild-cognitive impaired (MCI), and AD subjects,
NEP2 mRNA expression levels in the mid-temporal gyrus were
found to be lowered in women with MCI compared to non-
impaired women (Huang et al., 2012). Furthermore, this altered
expression was found to have a sexually dimorphic change, with
males with MCI having significantly elevated NEP2 mRNA levels
compared to non-impaired males in the mid-temporal and mid-
frontal gyri. However, levels of NEP2 mRNA in those with AD
were not different from non-impaired controls. These expression
profiles closely followed what was measured for NEP in the mid-
temporal gyrus. These data suggest that there is a dysregulation
of NEP-like enzyme mRNA levels early in the pathogenesis of
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 187 | 3
Marr and Hafez NEP2 in Alzheimer’s disease
FIGURE 1 | Summary of known murine and human NEP2 splice
forms. This figure represents the protein sequences of NEP2 isoforms
and summarizes their localizations and Aβ-degrading activity. The murine
α-form is missing amino acids (a.a.) 41–63 which contains a furin-like
processing site (red line) leaving this form membrane bound. The murine
β-form contains this sequence and is secreted. The murine γ-form is
missing a.a. 41–63 but contains an insertion at a.a. 311–347. All the
known human forms of NEP2 contain the furin-like processing site. The
β-form of human NEP2 is 77% identical to the murine β-form and is
secreted. The human γ-form is missing a.a. 152–308 and is not secreted.
Because of an alternate splice acceptor site, the δ-form of human NEP2
is knocked out of frame resulting in early termination and absence of the
critical zinc-binding motif (HEITH). IC, intracellular; PM, plasma
membrane; EC/LUM, extracellular or luminal; * associated with the
membrane fraction and located inside the cell (Ikeda et al., 1999);
however, in vitro expression did show the ability to degrade extracellular
Aβ (Hafez et al., 2011); ** primarily secreted (Ghaddar et al., 2000) but
also found in the membrane fraction (Ikeda et al., 1999; Raharjo et al.,
2001; Shirotani et al., 2001). # associated with the membrane fraction
and secreted (Whyteside and Turner, 2008); however, also shown to be
expressed on the cell surface and to degrade extracellular Aβ (Huang
et al., 2008); † Aβ-degrading activity found only at the extracellular
surface (Huang et al., 2008); ‡ found in the total cell lysate (subcellular
compartment localization not done) (Huang et al., 2008).
AD. Huang et al. (2012) also used an immunodepletion/activity
assay to detect NEP2 activity in brain specimens and found
reduced activity in association with MCI and AD regardless of
sex. Therefore, this initial study suggests that NEP2 activity is
reduced in association with AD, which is contrary to most of
the findings with other Aβ degrading proteases (discussed above).
Finally, it was also shown that NEP2 mRNA can be detected in
the peripheral blood of humans. These data suggest the poten-
tial of NEP2 assays to serve as preclinical mRNA expression or
enzyme activity markers for AD if expression levels in the brain
mimic what is present in the blood or cerebrospinal fluid. Many
neural pathologies including AD can be reflected in changes in
gene expression, splicing, and protein profiles in blood and CSF,
providing precedent for examining gene expression in these body
fluids (Tang et al., 2005; Blennow et al., 2010; Courtney et al.,
2010; Wu et al., 2011; Leuner et al., 2012; Mapstone et al., 2014).
The search for new preclinical biomarkers is important given
that the identification of biomarkers in AD has been relatively
unsuccessful. In a recent systematic review of 59 studies, McGhee
et al. (2014) found insufficient evidence to recommend using any
biomarker as an outcome measure in disease progression. This
highlights the importance of finding tools like NEP2 expression
to detect AD early in disease progression.
CONCLUSION
The impact that Alzheimer’s disease will have on the future of
medicine over the next 40 years cannot be understated, and the
accumulation of Aβ is currently the best theory to describe the
main drive for the overall disease process. Therefore continued
research into the mechanisms of Aβ clearance remains of upmost
importance. The discovery of endopeptidases that degrade Aβ,
such as NEP and NEP2 highlight an avenue of intervention via
viral-mediated gene therapy. While NEP studies have produced
encouraging results, studies utilizing NEP2 as a therapeutic agent
are still warranted as NEP2 may be more selective for Aβ (Whyte-
side and Turner, 2008). Studies are also needed to evaluate the
effectiveness of NEP2 assays as a potential molecular marker for
the disease.
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